ReviewCancers2024
Targeted Therapeutic Strategies for the Treatment of Cancer.
Review in Cancers, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed.
- Jujube Peel Pigment-Loaded Thermosensitive Hydrogel with In Vitro Pro-Apoptotic and Antibacterial Activities.Gels (Basel, Switzerland) · 2026Article
- Thieno[3,2-International journal of molecular sciences · 2026Review
- Ligand-modified liposomes as drug delivery systems for the active targeting of pancreatic cancer.International journal of pharmaceutics: X · 2026Review
- Synthesis and Characterization of Sulfonamide-Schiff Bases, and Investigation of Cytotoxic, Antioxidant, HDAC, and Apoptotic Activities in Human Colon Cancer Cells (DLD-1 and HT-29).Archiv der Pharmazie · 2026Article
- How do vibration stimulation frequencies affect the nonlinear dynamics and mechanical characterization of breast cancer cells?Biochemistry and biophysics reports · 2026Article
- New Phenylpropanoid fromCurrent pharmaceutical design · 2026Review
- Protein Engineering and Drug Discovery: Importance, Methodologies, Challenges, and Prospects.Biomolecules · 2025Review
- Review
- Article
- Combination of hydralazine and all-trans retinoic acid targeting breast cancer cells.BMC cancer · 2025Article
- Recent Advances in Anti-Cancer Drugs.International journal of molecular sciences · 2025Article
- Mesenchymal Stem Cell-Conditioned Media-Derived Exosomes Loaded WithFood science & nutrition · 2025Article
- Critical Review on Molecular Mechanisms for Genistein's Beneficial Effects on Health Through Oxidative Stress Reduction.Antioxidants (Basel, Switzerland) · 2025Review
- The Potential of Peptide-Based Inhibitors in Disrupting Protein-Protein Interactions for Targeted Cancer Therapy.International journal of molecular sciences · 2025Review
- Exosomes derived from natural killer cells: transforming immunotherapy for aggressive breast cancer.Medical oncology (Northwood, London, England) · 2025Review
- Advances in Materials Science for Precision Melanoma Therapy: Nanotechnology-Enhanced Drug Delivery Systems.Pharmaceutics · 2025Review
- Recent Advances in Metal-Organic Framework-Based Anticancer Hydrogels.Gels (Basel, Switzerland) · 2025Review
- Aptamers in Combination Therapies for Enhanced Radiosensitization in Cancer.Iranian journal of biotechnology · 2025Review
- Mouse pancreatic tumor organoids reveal synergistic efficacy of low-dose anticancer drug and radiation combinations.Frontiers in medicine · 2025Article
- Identifications of Similarity Metrics for Patients With Cancer: Protocol for a Scoping Review.JMIR research protocols · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Extensive research is underway to develop new therapeutic strategies to counteract therapy resistance in cancers. This review presents various strategies to achieve this objective. First, we discuss different vectorization platforms capable of releasing drugs in cancer cells. Second, we delve into multitarget therapies using drug combinations and dual anticancer agents. This section will describe examples of multitarget therapies that have been used to treat solid tumors.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.